{
    "clinical_study": {
        "@rank": "109405", 
        "arm_group": [
            {
                "arm_group_label": "Ozenoxacin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority\n      clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical\n      diagnosis of non-bullous or bullous impetigo."
        }, 
        "brief_title": "Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo", 
        "condition": "Impetigo", 
        "condition_browse": {
            "mesh_term": "Impetigo"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of bullous or non bullous impetigo. The patient has a total\n             affected area comprised between 1-100 cm2 with surrounding erythema not extending\n             more than 2 cm from the edge of any affected area. In case of multiple affected areas\n             the total area will be the sum of each affected area and will not exceed 100 cm2.\n             Additionally for patients < 12 years the total area will not exceed a maximum of 2%\n             of the body surface area.\n\n          -  Total Skin Infection Rating Scale (SIRS) score of at least 3, including pus/exudate\n             score of at least 1\n\n        Exclusion Criteria:\n\n          -  Has a bacterial infection, which in the opinion of the investigator, could not be\n             appropriately treated by a topical antibiotic.\n\n          -  Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary\n             temperature over 37.2 \u00b0C (99.0 \u00b0F)"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Months"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090764", 
            "org_study_id": "P-110881-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ozenoxacin", 
                "intervention_name": "Ozenoxacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 17, 2014", 
        "official_title": "A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States and Puerto Rico: Food and Drug Administration", 
                "South Africa: Medicines Control Council", 
                "Germany: The Bavarian State Ministry of the Environment and Public Health", 
                "Romania: Ministry of Public Health", 
                "Spain: Ministry of Health", 
                "Russia: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Clinical Response", 
            "safety_issue": "No", 
            "time_frame": "Visit 3 (Day 6-7)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ferrer Internacional S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferrer Internacional S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}